Hint mode is switched on Switch off

ArriVent Biopharma, ordinary share
AVBP, US04272N1028

Add a stock to WL
Choose all Reset all
ArriVent Biopharma, сountry — USA
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
No data
from
to
ADD-IN
Cbonds add-in API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Unlock data Watch full tour

Latest quotes

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Analysts forecasts

  • median ***
  • average ***
  • min ***
  • max ***

Issuer

Profile
ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products. With a deep and global network, ArriVent seeks to access unique and best-in-class drug candidates at various development stages, including those coming from China ...
ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products. With a deep and global network, ArriVent seeks to access unique and best-in-class drug candidates at various development stages, including those coming from China and other emerging biotech hubs. Through strategic collaborations with innovative biopharma companies, ArriVent aims to globalize medicines for patients with unmet medical need in a broad range of diseases, with an initial focus in oncology.
Show more Hide
  • Issuer
  • Full borrower / issuer name
    ArriVent Biopharma Inc
  • Industry
    Pharmaceutical Preparation and Biotechnology

Placement data

  • Placement type
    IPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    AVBP
  • Placement
    26.01.2024
  • Lock up period
    180
  • Number of papers
    9,722,222
  • Volume of raised funds
    175 mln USD
  • Placement share
    30.42%
  • Final placement price
    18 USD
  • Price change since placement date
    -100%
  • By capitalization
    575.22 mln USD

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
Show all Hide

Related Stock indices

Indicators

News

11/05/2026 ArriVent Biopharma: Other Events, Financial Statements And Exhibits
10/11/2025 ArriVent Biopharma: Results Of Operations And Financial Condition, Financial Statements And Exhibits
09/09/2025 ArriVent Biopharma: ​, Financial Statements And Exhibits
21/07/2025 ArriVent Biopharma: Item
01/07/2025 ArriVent Biopharma: Entry Into A Material Definitive Agreement, Other Events
All organization news

Holders

Industry Leaders

Registration is required to get access.